Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently updated its clinical study ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

A large trial in a primary care setting found daily emollient use to be safe, feasible, and effective in reducing atopic ...

Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, ...

Experts disagree on best strategies to prevent a rare, devastating complication: when patients with diffuse large B-cell ...

The FGFR inhibitors market is projected to witness substantial growth in the coming years, driven by the rising incidence of conditions such as urothelial carcinoma, cholangiocarcinoma, and ...

Getting back to the new screen, these 20 companies in the S&P 500 have shown the largest increases in sales per share while also improving gross and operating margins from their year-earlier fiscal ...